re: sbp long term trade
paladin boy it will be 5 years before available
Solbec cancer drug given orphan status by FDA 12:46, Friday, 11 November 2005
Sydney - Friday - November 11: (RWE Australian Business News) - Solbec Pharmaceuticals Limited (ASX: SBP) today announced that it has received orphan drug designation from the US Food and Drug Administration (FDA) for its lead anti-cancer compound Coramsine for the treatment of metastatic renal cell carcinoma. Solbec's strategy is to pursue an aggressive timeline to advance Coramsine® to the market within 3-5 years. This will be achieved by targeting orphan drug indications such as metastatic renal cell carcinoma. Orphan drug status is a useful method for compressing the clinical development timeframe from 5-9 years down to as little as 2-3 years. Other benefits include: market protection upon registration (7 years against generic products), a reduction in clinical data required for product registration, tax incentives and reduced filing fees. In granting orphan drug status for Coramsine, the FDA is essentially acknowledging Coramsine's potential ability to improve the currently low survival rate of metastatic renal cell carcinoma
SBP Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held